1 results match your criteria: "University Paris-Sud UMR 007[Affiliation]"
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Cancer
May 2017
CEA, Institute of Emerging Diseases and Innovative Therapies, University Paris-Sud UMR 007, Fontenay-aux-Roses, France.
Article Synopsis
- Researchers tested if adding a drug called pioglitazone to the treatment of chronic myeloid leukemia (CML) would help patients improve their condition while they were also taking imatinib.
- Twenty-four patients were involved in the study, and they monitored the effects and any side effects of the combination treatment over a year.
- The results showed that about 56% of patients improved to a better treatment level, and the drugs seemed safe to use together, but more research is needed to confirm these findings.